James Kimmel, Jr., is a lecturer of psychiatry at the Yale School of Medicine, a lawyer, and the founder and co-director of the Yale Collaborative for Motive Control Studies. He is the creator of The ...

What’s driving the permanent crisis of drug addiction? To express the ambient feeling that “things are getting worse,” there exists, of course, a meme. It plots iterations of a chart, and on its ...

First-person stories of drug addiction, hope, healing, and recovery. Addiction is a complex and often misunderstood condition. This gripping special provides raw, unfiltered access to first-person ...

A drug called buprenorphine may be the best tool doctors have to fight the fentanyl crisis. Why hasn’t it been more widely adopted? A dose of buprenorphine, an ...

Evidence is mounting that the wildly popular weight-loss medicines known as GLP-1s may also hold potential for treating addiction, and the field may be on the verge of obtaining desperately needed ...

Drug addiction carries an extremely high risk of relapse, as cravings can be reignited by minor stimuli even long after one has stopped using. Previously, this phenomenon was attributed to a decline ...

Preclinical studies in animals have already shown that GLP-1 drugs can reduce reward-seeking behavior. Early clinical work in humans has begun to hint at similar effects. A randomized trial of ...

Scientists don’t yet fully understand how GLP-1 drugs like Ozempic affect the brain’s reward pathways, but there are promising signals about how they control cravings. Also in the Global Health ...

Researchers at Washington University School of Medicine in St. Louis found that drugs known as GLP‑1 receptor agonists appear to reduce the risk of substance-use disorders and serious harms linked to ...